Risdiplam Patent Expiration
Risdiplam is Used for treating spinal muscular atrophy. It was first introduced by Genentech Inc
Risdiplam Patents
Given below is the list of patents protecting Risdiplam, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Evrysdi | US12122789 | Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making | Apr 15, 2041 | Genentech Inc |
| Evrysdi | US11534444 | Treatment of SMA | Oct 04, 2038 | Genentech Inc |
| Evrysdi | US12350273 | Treatment Of Sma | Oct 01, 2038 | Genentech Inc |
| Evrysdi | US11938136 | Compositions for treating spinal muscular atrophy | Nov 08, 2036 | Genentech Inc |
| Evrysdi | US11827646 | Compounds for treating spinal muscular atrophy | Jan 25, 2036 | Genentech Inc |
| Evrysdi | US9969754 | Compounds for treating spinal muscular atrophy | May 11, 2035 | Genentech Inc |
| Evrysdi | US9586955 | Compounds for treating spinal muscular atrophy | Feb 08, 2033 | Genentech Inc |
Risdiplam's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Risdiplam:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
